Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Protein Degradation Therapy Market Growth Potential: How Will Market Size Change Through 2030?
The protein degradation therapy market has experienced robust expansion in recent times, with its size projected to increase from $1.25 billion in 2025 to $1.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical growth has been propelled by progress in molecular biology research, the broadening scope of targeted cancer treatments, a deeper comprehension of protein dysfunction across various diseases, promising results in early-phase clinical trials, and a surge in venture capital investment within the biotechnology sector.
The protein degradation therapy market is projected to experience robust expansion over the coming years, reaching a valuation of $1.83 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period is fueled by a heightened demand for innovative cancer treatments, increased funding directed toward precision oncology, the broadening of protein degradation technology platforms, a surge in clinical trial initiatives, and enhanced regulatory backing for novel therapeutic approaches. Key developments shaping this period include the accelerated creation of targeted protein degraders, a pronounced emphasis on oncology-related uses, greater investment in PROTAC-based therapies, an expanding roster of clinical pipeline candidates, and strengthened partnerships between pharmaceutical companies and biotechnology firms.
Download A Free Sample Report For Comprehensive Market Insights:
Protein Degradation Therapy Market Growth Drivers And Industry Catalysts
The rising prevalence of cancer is anticipated to drive expansion in the protein degradation therapy market moving forward. Cancer encompasses a spectrum of disorders characterized by abnormal cell growth and spread throughout the body. Its incidence is climbing largely due to a mix of influences, with an aging populace as a key factor. Lifestyle choices, including tobacco use, unhealthy eating, insufficient exercise, and growing obesity rates, have also elevated the likelihood of developing various cancers. Protein degradation therapy is essential in cancer treatment because it identifies and removes specific proteins responsible for fueling cancer progression and survival, potentially bypassing resistance to conventional therapies. As an example, in February 2024, a report from the World Health Organization, an intergovernmental body based in Switzerland, projected over 35 million new cancer cases globally by 2050, marking a 77% rise from the estimated 20 million cases in 2022. Furthermore, nations with a high human development index (HDI) are expected to experience the most significant absolute increase, with an extra 4.8 million new cases predicted by 2050 relative to 2022 figures. Consequently, the increasing cancer burden is fueling growth in the protein degradation therapy market.
Protein Degradation Therapy Market Segment Landscape: Which Areas Lead Market Development?
The protein degradation therapy market covered in this report is segmented –
1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)
2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications
3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy
2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy
Protein Degradation Therapy Market Trends Influencing Long-Term Demand
Leading companies in the protein degradation therapy sector are increasingly turning to strategic partnerships as a means to create groundbreaking treatments, pool complementary skills, share available resources, and speed up the process of identifying and advancing new drug candidates that target proteins responsible for disease. Such collaborations allow firms to tap into each other’s unique capabilities and assets, fostering mutual advantages and collective accomplishment. A notable example occurred in February 2024, when Arvinas, a biotechnology firm based in the United States, unveiled its first orally administered PROTAC degrader, designated ARV-102. This compound is engineered to penetrate the blood-brain barrier and specifically act on LRRK2, with applications aimed at neurodegenerative conditions. ARV-102 exhibits oral bioavailability, a profile capable of crossing into the brain, and a strong affinity for LRRK2. By tackling targets previously considered undruggable, this advancement bolsters the pipelines of companies in this space, although obstacles persist regarding sustained safety, intricacies in manufacturing, and the fine-tuning of pharmacokinetic properties due to the compound’s larger molecular dimensions.
Protein Degradation Therapy Market Industry Leaders And Market Competition
Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc
Access The Complete Protein Degradation Therapy Market Report:
Protein Degradation Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model